Cipla’s wholly-owned subsidiary, Goldencross Pharma Private Ltd, on Monday, signed an agreement to acquire 11.71 per cent stake in Wellthy Therapeutics Private Ltd for ₹10.5 crore. The transaction is expected to be completed by March 10. Cipla and Wellthy have entered into a partnership to offer a combination of pharmacotherapy and digital therapeutics for improved patient outcomes in the chronic therapies of diabetology and cardiology.
Cipla takes stake in Wellthy Therapeutics
Published on
February 19, 2019 00:00